Monte Rosa Therapeutics (NASDAQ:GLUE) reported a net loss of $46.1 million for the fourth quarter ended December 31, 2025.
On a per-share basis, the Boston-based biotechnology firm posted a loss of 55 cents, missing the Zacks Investment Research consensus estimate of a 47-cent loss.
The wider-than-expected deficit reflects increased research and development costs associated with the company’s expanding clinical portfolio, including its lead inflammatory and oncology programs.
Revenue for the quarter came in at $2.8 million, significantly trailing the $10.3 million projected by analysts.
This quarterly volatility in the top line is often characteristic of clinical-stage biotechs that rely on the timing of milestone payments from large-scale partnerships.
Despite the quiet fourth quarter, the company’s full-year performance told a different story; total revenue for 2025 reached $123.7 million, bolstered by significant upfront payments and collaboration credits earned earlier in the fiscal year from partners like Novartis and Roche.
For the full year 2025, Monte Rosa reported a total net loss of $38.6 million, or 46 cents per share.
Management noted that while the quarterly figures fluctuated, the company remains in a strong capital position following its successful $345 million follow-on financing.
With cash and marketable securities totaling $382.1 million, Monte Rosa has a projected operational runway that extends into 2029.